The chairman is the bank, and the bank gets equity

The weird thing about Galectin Therapeutics' capital structure is not that it has debt. It's that the debt is all owed to one person, that person sits on the board, and he already owns more stock than almost anyone else.

Galectin Therapeutics, a clinical-stage biotech trading at $3.03, has borrowed at least $111 million from its own chairman, Richard E. Uihlein. Some of it is in the form of convertible promissory notes. Most of it is on a revolving credit line. Either way, Uihlein - who already owns roughly 15.7% of the company - can convert that debt into common stock at the closing price on the date each note was drawn, but no less than $3.00 per share. He also gets warrants, exercisable at 150% of that same closing price.

The company's press releases describe this as "strengthening the balance sheet." That is a funny way to describe what is, structurally, a recapitalization in slow motion.

The simplest model is this: Uihlein is both the bank and the lead equity holder. The credit lines function like a revolving warehouse facility - the kind of structure you see when a company can't raise equity on acceptable terms, so a patient investor puts cash on a line and takes equity kickers in return. Except here, the "patient investor" is also the chairman, which means the governance question is not whether the terms are fair but whether the terms were negotiated with the same rigor they would be if the lender sat in the other room.

The plumbing is straightforward enough to follow. Since 2021, Uihlein has provided the company with $20 million in convertible notes (originally at a steep 228% conversion premium), then a series of revolving credit lines that have accumulated $81 million in borrowings. In July 2025, he added another $10 million credit line. In December 2025, he added yet another $10 million line. Borrowings carry interest at the short-term Applicable Federal Rate - currently about 4.05% - plus 2%, so roughly 6.05%. The notes can't be prepaid without Uihlein's consent.

Each draw comes with warrants: 20,000 per $1 million borrowed, exercisable at 150% of the closing price on the note date, capped at $10.00 and floored at $3.00. A registration rights agreement means shares issued on conversion can be sold into the public market within 180 days.

Per Galectin's S-3 shelf filing in March 2026, there are 33.6 million shares issuable upon conversion of the credit line, plus additional shares from the convertible notes. For context, Galectin has roughly 66 million shares outstanding today. If Uihlein converts the full outstanding balance at the $3.00 floor, that is on the order of 37 million new shares - more than half the current float. Existing shareholders would be diluted by roughly 36%.

The company would describe this as removing debt from the balance sheet and replacing it with equity. And mechanically, that's what conversion does. But the real question isn't whether the balance sheet looks cleaner afterward. It's who is getting the equity at what price, and what that implies about the company's ability to raise capital from anyone else.

Let me stage a tiny dialogue, because incentives are easier to see when you assign them to speakers.

Market investor: Why would you lend $111 million to a drug company with no revenue and a $31 million annual net loss?

Uihlein: Because I get to convert at $3.00 minimum, plus warrants at $4.50 minimum, and I already believe the pipeline is worth more than that.

Existing shareholder: And if the stock never gets back above $3?

Uihlein: Then the conversion happens at $3 anyway, which is still the best entry price anyone will have.

The point is not that Uihlein is doing anything wrong. The point is that the structure is deliberately advantageous to him. A $3.00 conversion floor on a stock trading at $3.03 is essentially converting at today's price. The warrants at 150% give him calls on upside with a built-in cushion. And the revolving nature of the credit line means he can extend new draws as the old ones mature - which, in fact, is exactly what has happened, with maturities pushed from 2024 to 2026 to 2027.

This is old-finance structure wearing a biotech wrapper. When a wealthy individual provides a revolving credit facility to a public company they sit on the board of, with equity kickers and conversion rights priced near the market, the arrangement functions as a permanent capital commitment. It keeps the company alive while the lender accumulates an enormous pool of cheap shares. Other shareholders get runway in exchange for eventual dilution.

The company's drug - belapectin, a galectin-3 inhibitor for MASH cirrhosis - has no approved indications and is pre-commercial. Galectin burned roughly $31 million in 2025 and had $14.1 million in cash at the end of the first quarter of 2026, with another $10 million available under the Uihlein credit line. Management says this extends the runway to April 2027. An FDA meeting is planned for the second quarter of 2026 to discuss next steps on the program.

The science matters, and the NAVIGATE dataset has shown some encouraging biomarker signals. But the capital structure tells you something the pipeline update does not: Galectin has not been able to raise meaningful equity capital from the open market in years. When a biotech with a $200 million market cap is running its balance sheet through its chairman's personal credit line, that is itself data about what outside investors are willing to pay.

The competitor framing of "strengthening the balance sheet" is technically true in the same way that refinancing your mortgage is "strengthening" your finances - the label on the obligation changes, and for a moment, things look tidier. The substance is that the company is dependent on one person's willingness to keep extending credit, and that person is capturing all the upside asymmetry the deal can provide.

If the drug works and a partnership or acquisition event pushes the stock to $10 or $15, Uihlein converts at $3.00 and exercises warrants at $4.50, and his returns are extraordinary. If the drug disappoints and the stock languishes near $3, he still converts at $3 and his loss is capped by the fact that he was already a major shareholder. The structure is designed so that the person keeping the lights on gets the best terms anyone will ever get on this stock.

That is not fraud. It is not even unusual in small-cap biotech. But it is worth understanding what you are looking at: a revolving credit facility disguised as balance sheet strength, where the bank, the chairman, and the largest shareholder are the same person, and the conversion mechanics ensure he wins in almost every outcome.